Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Abemaciclib;   Drug: Nivolumab;   Procedure: Tumor biopsy;   Procedure: Peripheral blood;   Other: EORTC QLQ-30 Sponsors:   Washington University School of Medicine;   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials